Pharmacokinetics and distribution of SN 28049, a novel DNA binding anticancer agent, in mice.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2010, v. 65, n. 6, p. 1145, doi. 10.1007/s00280-009-1123-5
- By:
- Publication type:
- Article
Works by Kestell, Philip
Results: 20
1
2
Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2004, v. 53, n. 5, p. 377, doi. 10.1007/s00280-003-0753-2
- By:
- Publication type:
- Article
3
Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2002, v. 50, n. 3, p. 186, doi. 10.1007/s00280-002-0482-y
- By:
- Publication type:
- Article
4
Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
- Published in:
- Cancer Chemotherapy & Pharmacology, 2002, v. 49, n. 2, p. 126, doi. 10.1007/s00280-001-0383-5
- By:
- Publication type:
- Article
5
Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice.
- Published in:
- 2002
- By:
- Publication type:
- journal article
6
A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2001, v. 47, n. 6, p. 541, doi. 10.1007/s002800100285
- By:
- Publication type:
- Article
7
Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
- Published in:
- 2001
- By:
- Publication type:
- journal article
8
In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2001, v. 47, n. 4, p. 319, doi. 10.1007/s002800000249
- By:
- Publication type:
- Article
9
Pharmacokinetics and metabolism of the nitrogen mustard bioreductive drug 5.
- Published in:
- 2000
- By:
- Publication type:
- journal article
10
Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2000, v. 46, n. 2, p. 135, doi. 10.1007/s002800000131
- By:
- Publication type:
- Article
11
Non-specific binding of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in liver microsomes from various species.
- Published in:
- Journal of Pharmacy & Pharmacology, 2002, v. 54, n. 7, p. 997, doi. 10.1211/002235702760089135
- By:
- Publication type:
- Article
12
Reversible binding of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid to plasma proteins and its distribution into blood cells in various species.
- Published in:
- Journal of Pharmacy & Pharmacology, 2001, v. 53, n. 4, p. 463, doi. 10.1211/0022357011775758
- By:
- Publication type:
- Article
13
Therapeutic reactivation of mutant p53 protein by quinazoline derivatives.
- Published in:
- 2012
- By:
- Publication type:
- Report
14
Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) by non-steroidal anti-inflammatory drugs.
- Published in:
- 2009
- By:
- Publication type:
- Report
15
Application of liquid chromatography–mass spectrometry to monitoring plasma cyclophosphamide levels in phase I trial cancer patients*.
- Published in:
- Clinical & Experimental Pharmacology & Physiology, 2004, v. 31, n. 10, p. 677, doi. 10.1111/j.1440-1681.2004.03065.x
- By:
- Publication type:
- Article
16
Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability.
- Published in:
- International Journal of Cancer, 2005, v. 116, n. 2, p. 322, doi. 10.1002/ijc.21005
- By:
- Publication type:
- Article
17
Comparison of a homologous series of benzonaphthyridine anti-cancer agents in mice: divergence between tumour and plasma pharmacokinetics.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 70, n. 1, p. 151, doi. 10.1007/s00280-012-1892-0
- By:
- Publication type:
- Article
18
Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes.
- Published in:
- British Journal of Clinical Pharmacology, 2001, v. 52, n. 2, p. 129, doi. 10.1046/j.0306-5251.2001.01438.x
- By:
- Publication type:
- Article
19
PREDICTING PHARMACOKINETICS AND DRUG INTERACTIONS IN PATIENTS FROM IN VITRO AND IN VIVO MODELS: THE EXPERIENCE WITH 5,6-DIMETHYLXANTHENONE-4-ACETIC ACID (DMXAA), AN ANTI-CANCER DRUG ELIMINATED MAINLY BY CONJUGATION.
- Published in:
- Drug Metabolism Reviews, 2002, v. 34, n. 4, p. 751, doi. 10.1081/DMR-120015693
- By:
- Publication type:
- Article
20
Studies on the mechanism of cancer protection by wheat bran: effects on the absorption, metabolism and excretion of the food carcinogen 2-amino-3-methylimidazo[4,5-f]quinoline (IQ).
- Published in:
- Carcinogenesis, 1999, v. 20, n. 12, p. 2253, doi. 10.1093/carcin/20.12.2253
- By:
- Publication type:
- Article